PCRRF yields 2.89% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 8
Combined, PCRRF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PCRRF + JNJ for your $10,000?
Pasco Corporation engages in the acquisition, analysis, and provision of geospatial information in Japan and internationally. It offers spaceborne services that handle data from the commercial earth observation satellites launched worldwide; and airborne surveying services, such as aerial photography, aerial laser, thermal sensor, hyperspectral sensor, oblique aerial photography, and airborne IFSAR surveying, as well as portable aerial photography and locator systems. The company also provides vehicle/ground surveying services, including road condition laser, road condition, global positioning system, total station, precision, and terrestrial laser surveying, as well as ground based InSAR and radar; and water area surveying services comprising bathymetry and seabed exploration. In addition, it offers geographic information system (GIS) cloud services for the municipalities and central government, cloud-based regional analysis and marketing services for the private companies, and reassurance with disaster prevention systems; customization and GIS application development; and geospatial information consulting services, including regional strategy analysis, disaster prevention and mitigation consultant, road and bridge design, water supply and sewage facility management, dam and port management, rivers and erosion control, mapping solutions, and maintenance services. The company was formerly known as Pacific Koku Sokuryo Co., Ltd. and changed its name to Pasco Corporation in 1983. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Pasco Corporation is a subsidiary of Secom Co., Ltd.
Full PCRRF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.